Loading...

You're on the old version of Simply Wall St. We will no longer be supporting this site, so we recommend you switch to our brand new platform.

Biophytis

DB:6XB
Snowflake Description

Imperfect balance sheet with weak fundamentals.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
6XB
DB
€21M
Market Cap
  1. Home
  2. DE
  3. Pharmaceuticals & Biotech
Company description

Biophytis SA, a clinical-stage biotechnology company, focuses on the development of therapeutics that slow the degenerative processes and improve functional outcomes for patients suffering from age-related diseases. The last earnings update was 22 days ago. More info.


Add to Portfolio Compare Print
  • Biophytis has significant price volatility in the past 3 months.
6XB Share Price and Events
7 Day Returns
154.2%
DB:6XB
5.2%
DE Biotechs
4.3%
DE Market
1 Year Returns
-51.1%
DB:6XB
-7.4%
DE Biotechs
-14.2%
DE Market
6XB Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
Biophytis (6XB) 154.2% 187.1% 223.1% -51.1% - -
DE Biotechs 5.2% -3.3% -20.3% -7.4% 19.5% -9.4%
DE Market 4.3% -9% -21.6% -14.2% -19.6% -25.6%
1 Year Return vs Industry and Market
  • 6XB underperformed the Biotechs industry which returned -7.4% over the past year.
  • 6XB underperformed the Market in Germany which returned -14.2% over the past year.
Price Volatility
6XB
Industry
5yr Volatility vs Market

Value

 Is Biophytis undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.

In this section, we usually try to help investors determine whether Biophytis is trading at an attractive price based on the cash flow it is expected to produce in the future. But as Biophytis has not provided consistent financial data, and the stock also has no analyst forecast or coverage, its intrinsic value cannot be reliably calculated by extrapolating past data or using analyst consensus cash flow predictions.

This is quite a rare situation as 89% of companies covered by Simply Wall St do have a valuation analysis. You can see them here.

Show me the analysis anyway

INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
  • It is not possible to calculate the future cash flow value for Biophytis. This is due to cash flow or dividend data being unavailable. The share price is €0.577.
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for Biophytis's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are Biophytis's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
DB:6XB PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2019-12-31) in EUR €-1.05
ENXTPA:ALBPS Share Price ** ENXTPA (2020-04-08) in EUR €0.54
Europe Biotechs Industry PE Ratio Median Figure of 24 Publicly-Listed Biotechs Companies 43.07x
Germany Market PE Ratio Median Figure of 402 Publicly-Listed Companies 17.07x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of Biophytis.

DB:6XB PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= ENXTPA:ALBPS Share Price ÷ EPS (both in EUR)

= 0.54 ÷ -1.05

-0.51x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Biophytis is loss making, we can't compare its value to the Europe Biotechs industry average.
  • Biophytis is loss making, we can't compare the value of its earnings to the Germany market.
Price based on expected Growth
Does Biophytis's expected growth come at a high price?
Raw Data
DB:6XB PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section -0.51x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 0 Analysts
Not available
Europe Biotechs Industry PEG Ratio Median Figure of 19 Publicly-Listed Biotechs Companies 1.71x
Germany Market PEG Ratio Median Figure of 256 Publicly-Listed Companies 1.24x

*Line of best fit is calculated by linear regression .

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to calculate PEG ratio for Biophytis, we can't assess if its growth is good value.
Price based on value of assets
What value do investors place on Biophytis's assets?
Raw Data
DB:6XB PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2019-12-31) in EUR €-0.20
ENXTPA:ALBPS Share Price * ENXTPA (2020-04-08) in EUR €0.54
Germany Biotechs Industry PB Ratio Median Figure of 14 Publicly-Listed Biotechs Companies 3.37x
Germany Market PB Ratio Median Figure of 573 Publicly-Listed Companies 1.47x
DB:6XB PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= ENXTPA:ALBPS Share Price ÷ Book Value per Share (both in EUR)

= 0.54 ÷ -0.20

-2.75x

* Primary Listing of Biophytis.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Biophytis has negative assets, we can't compare the value of its assets to the DE Biotechs industry average.

Next steps:

  1. Take a look at our analysis of 6XB’s management and see if the CEO’s compensation is within a reasonable range, who is on the board and if insiders have been trading lately.
  2. When valuing a company like this, investors focus more on how they perceive the size of the opportunity, the company's ability to deliver and scale, and the strength of the team. While we are not analysing this type of data at the moment, if you don’t know where to start, we recommend reading through Biophytis's regulatory filings and announcements.
  3. Show me more potentially undervalued companies in the Biotechs industry
  4. Use fundamentals to screen for another stock to analyse from our database of over 75,000 companies worldwide
X
Value checks
We assess Biophytis's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Biotechs industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Biotechs industry average (and greater than 0)? (1 check)
  5. Biophytis has a total score of 0/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

Future Performance

 How is Biophytis expected to perform in the next 1 to 3 years based on estimates from 0 analysts?

In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Biophytis has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by Simply Wall St do have past financial data. You can see them here.

Show me the analysis anyway

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
38.2%
Expected Biotechs industry annual growth in earnings.
Earnings growth vs Low Risk Savings
Is Biophytis expected to grow at an attractive rate?
  • Unable to compare Biophytis's earnings growth to the low risk savings rate as no estimate data is available.
Growth vs Market Checks
  • Unable to compare Biophytis's earnings growth to the Germany market average as no estimate data is available.
  • Unable to compare Biophytis's revenue growth to the Germany market average as no estimate data is available.
Annual Growth Rates Comparison
Raw Data
DB:6XB Future Growth Rates Data Sources
Data Point Source Value (per year)
Germany Biotechs Industry Earnings Growth Rate Market Cap Weighted Average 38.2%
Germany Biotechs Industry Revenue Growth Rate Market Cap Weighted Average 26.2%
Germany Market Earnings Growth Rate Market Cap Weighted Average 14.1%
Germany Market Revenue Growth Rate Market Cap Weighted Average 3.9%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
DB:6XB Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 0 Analyst Estimates (S&P Global) See Below
All numbers in EUR Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
DB:6XB Future Estimates Data
Date (Data in EUR Millions) Revenue Cash Flow Net Income * Avg. No. Analysts
DB:6XB Past Financials Data
Date (Data in EUR Millions) Revenue Cash Flow Net Income *
2019-12-31 -18
2019-09-30 -18
2019-06-30 -16 -18
2019-03-31 -14 -15
2018-12-31 -12 -14
2018-09-30 -11 -13
2018-06-30 -10 -12
2018-03-31 -10 -12
2017-12-31 -9 -11
2017-09-30 -9 -10
2017-06-30 -9 -9
2017-03-31 -8 -9

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • Unable to determine if Biophytis is high growth as no earnings estimate data is available.
  • Unable to determine if Biophytis is high growth as no revenue estimate data is available.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
DB:6XB Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 0 Analyst Estimates (S&P Global) See Below

All data from Biophytis Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

DB:6XB Future Estimates Data
Date (Data in EUR Millions) EPS * EPS High Estimate EPS Low Estimate Avg. No. Analysts
DB:6XB Past Financials Data
Date (Data in EUR Millions) EPS *
2019-12-31 -1.05
2019-09-30 -1.20
2019-06-30 -1.38
2019-03-31 -1.10
2018-12-31 -1.04
2018-09-30 -0.97
2018-06-30 -0.98
2018-03-31 -1.09
2017-12-31 -1.24
2017-09-30 -1.30
2017-06-30 -1.39
2017-03-31 -1.34

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • Unable to establish if Biophytis will efficiently use shareholders’ funds in the future without estimates of Return on Equity.

Next steps:

  1. Take a look at our analysis of 6XB’s management and see if the CEO’s compensation is within a reasonable range, who is on the board and if insiders have been trading lately.
  2. Biophytis's future outlook can be gauged by looking at industry trends and market size, and determining how well-positioned the company is compared to its competitors. Take a look at other high-growth Pharmaceuticals & Biotech companies here
  3. Biophytis's competitive advantages and company strategy can generally be found in its financial reports archived here.
  4. Use fundamentals to screen for another stock to analyse from our database of over 75,000 companies worldwide
X
Future performance checks
We assess Biophytis's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the Germany market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the Germany market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
Biophytis has a total score of 0/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

Past Performance

  How has Biophytis performed over the past 5 years?

The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare Biophytis's growth in the last year to its industry (Biotechs).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • Biophytis does not make a profit and their year on year earnings growth rate was negative over the past 5 years.
  • Unable to compare Biophytis's 1-year earnings growth to the 5-year average as it is not currently profitable.
  • Unable to compare Biophytis's 1-year growth to the Europe Biotechs industry average as it is not currently profitable.
Earnings and Revenue History
Biophytis's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from Biophytis Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

DB:6XB Past Revenue, Cash Flow and Net Income Data
Date (Data in EUR Millions) Revenue Net Income * G+A Expenses R&D Expenses
2019-12-31 -17.79 6.59 9.09
2019-09-30 -18.14 7.09 9.65
2019-06-30 -18.50 7.60 10.21
2019-03-31 -14.81 4.69 9.79
2018-12-31 -13.99 4.35 9.51
2018-09-30 -13.04 3.75 8.89
2018-06-30 -12.09 3.16 8.27
2018-03-31 -11.81 3.11 7.60
2017-12-31 -11.41 2.87 7.04
2017-09-30 -10.33 2.77 6.37
2017-06-30 -9.25 2.68 5.71
2017-03-31 -8.60 2.75 5.41
2016-12-31 -7.95 2.82 5.12
2016-09-30 -7.59 3.11 4.44
2016-06-30 -7.22 3.40 3.75
2016-03-31 -6.23 3.24 2.86
2015-12-31 -5.23 3.07 1.97
2015-09-30 -3.67 2.17 1.33
2015-06-30 -2.11 1.27 0.69
2015-03-31 -1.41 0.87 0.45
2014-12-31 -0.71 0.46 0.20
2013-12-31 -0.52 0.57 -0.03

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • It is difficult to establish if Biophytis has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) due to its liabilities exceeding its assets.
  • It is difficult to establish if Biophytis has efficiently used its assets last year compared to the Europe Biotechs industry average (Return on Assets) as it is loss-making.
  • It is difficult to establish if Biophytis improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.
X
Past performance checks
We assess Biophytis's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Biotechs industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
Biophytis has a total score of 0/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

Health

 How is Biophytis's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up Biophytis's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • Biophytis is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
  • Biophytis's cash and other short term assets cover its long term commitments.
Balance sheet
This treemap shows a more detailed breakdown of Biophytis's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • Low level of unsold assets.
  • Biophytis has negative shareholder equity (liabilities exceed assets) therefore debt is not covered by short term assets.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from Biophytis Company Filings, last reported 3 months ago.

DB:6XB Past Debt and Equity Data
Date (Data in EUR Millions) Total Equity Total Debt Cash & Short Term Investments
2019-12-31
2019-09-30 -2.63 10.30 5.21
2019-06-30 -2.63 4.61 5.21
2019-03-31 2.38 10.55 11.15
2018-12-31 7.01 8.15 14.41
2018-09-30 7.01 8.15 14.41
2018-06-30 15.65 1.32 14.12
2018-03-31 21.19 1.01 19.86
2017-12-31 21.19 0.92 19.86
2017-09-30 21.19 0.92 19.86
2017-06-30 7.00 0.95 4.39
2017-03-31 7.00 0.95 4.39
2016-12-31 4.52 0.95 3.07
2016-09-30 4.52 0.95 3.07
2016-06-30 8.25 0.34 6.81
2016-03-31 8.25 0.34 6.81
2015-12-31 11.60 0.63 9.41
2015-09-30 11.60 0.63 9.41
2015-06-30 -2.21 2.55 1.60
2015-03-31 -2.21 2.55 1.60
2014-12-31 -1.13 0.72 0.01
2013-12-31 -0.41 0.46 0.04
  • Biophytis has negative shareholder equity (liabilities exceed assets), this is a more serious situation compared with a high debt level.
  • Irrelevant to check if Biophytis's debt level has increased considering it has negative shareholder equity.
  • Operating cash flow is negative therefore debt is not well covered.
  • Unable to confirm if the interest payments on Biophytis's debt are well covered by earnings due to lack of past financial data.
X
Financial health checks
We assess Biophytis's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. Biophytis has a total score of 2/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

Dividends

 What is Biophytis's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
0%
Current annual income from Biophytis dividends.
If you bought €2,000 of Biophytis shares you are expected to receive €0 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Unable to evaluate Biophytis's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
  • Unable to evaluate Biophytis's dividend against the top 25% market benchmark as the company has not reported any payouts.
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
DB:6XB Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 0 Analyst Estimates (S&P Global) See Below
Europe Biotechs Industry Average Dividend Yield Market Cap Weighted Average of 9 Stocks 1.1%
Germany Market Average Dividend Yield Market Cap Weighted Average of 314 Stocks 3.6%
Germany Minimum Threshold Dividend Yield 10th Percentile 0.8%
Germany Bottom 25% Dividend Yield 25th Percentile 1.6%
Germany Top 25% Dividend Yield 75th Percentile 4.6%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

DB:6XB Future Dividends Estimate Data
Date (Data in €) Dividend per Share (annual) Avg. No. Analysts

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to perform a dividend volatility check as Biophytis has not reported any payouts.
  • Unable to verify if Biophytis's dividend has been increasing as the company has not reported any payouts.
Current Payout to shareholders
What portion of Biophytis's earnings are paid to the shareholders as a dividend.
  • Unable to calculate sustainability of dividends as Biophytis has not reported any payouts.
Future Payout to shareholders
  • Insufficient estimate data to determine if a dividend will be paid in 3 years and that it will be sustainable.
X
Income/ dividend checks
We assess Biophytis's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 0.8%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can Biophytis afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. Biophytis has a total score of 0/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

Management

 What is the CEO of Biophytis's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
CEO
Stanislas Veillet
COMPENSATION €295,232
AGE 52
CEO Bio

Mr. Stanislas Veillet, Ph.D. serves as the Chairman of the Board and Chief Executive Officer of Biophytis SA. He has served as a Director at Drone Volt SA since May 4, 2018. Mr. Veillet served as Director of Research at Cargill. Mr. Veillet created Biophytis in 2006. Mr. Veillet is an Agronomist and a Doctor in genetics. Mr. Veillet worked for large multinational companies: Pharmacia and Danone. Mr. Veillet is an Expert in the areas of nutrition and health.

CEO Compensation
  • Stanislas's compensation has been consistent with company performance over the past year, both up more than 20%.
  • Stanislas's remuneration is about average for companies of similar size in Germany.
Management Team

Stanislas Veillet

TITLE
Chairman of the Board & CEO
COMPENSATION
€295K
AGE
52

Evelyne Nguyen

TITLE
Chief Financial Officer
AGE
57

Waly Dioh

TITLE
Chief Operating Officer

Pierre Dilda

TITLE
Chief Scientific Officer

Samuel Agus

TITLE
Chief Medical Officer
AGE
51
TENURE
2.3 yrs

_ Teylan

TITLE
Financial Controller
Board of Directors Tenure

Average tenure and age of the Biophytis board of directors in years:

3.9
Average Tenure
53
Average Age
  • The tenure for the Biophytis board of directors is about average.
Board of Directors

Stanislas Veillet

TITLE
Chairman of the Board & CEO
COMPENSATION
€295K
AGE
52

Jean Mariani

TITLE
Chairman of Scientific Advisory Board & Director
TENURE
4 yrs

Nadine Coulm

TITLE
Independent Director
AGE
56
TENURE
5.3 yrs

René Lafont

TITLE
Scientific Director & Member of Scientific Advisory Board
AGE
72

José-Alain Sahel

TITLE
Member of Scientific Advisory Board

Thomas Voit

TITLE
Member of Scientific Advisory Board
TENURE
2.5 yrs

Ivana Kim

TITLE
Member of Scientific Advisory Board
TENURE
3.9 yrs

Roger Fielding

TITLE
Member of Scientific Advisory Board
TENURE
3.9 yrs

Jean Franchi

TITLE
Independent Director
AGE
53
TENURE
2.8 yrs

Dimitri Batsis

TITLE
Independent Director
AGE
52
TENURE
2.3 yrs
Who owns this company?
Recent Insider Trading
  • No 3 month open market individual insider trading information.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price (€) Value (€)
X
Management checks
We assess Biophytis's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. Biophytis has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

News

Simply Wall St News

Company Info

Description

Biophytis SA, a clinical-stage biotechnology company, focuses on the development of therapeutics that slow the degenerative processes and improve functional outcomes for patients suffering from age-related diseases. Its therapeutics focuses on targeting and activating key biological resilience pathways that could protect against and counteract the effects of the multiple biological and environmental stresses that lead to age-related diseases. The company’s lead drug candidate, Sarconeos (BIO101), is an orally administered small molecule in development for the treatment of neuromuscular diseases, including sarcopenia and Duchenne muscular dystrophy (DMD). Its second drug candidate, Macuneos (BIO201), is an orally administered small molecule in development for the treatment of retinal diseases, including dry ager elated macular degeneration (AMD) and Stargardt disease. Biophytis SA has a collaboration agreement with AFM-Telethon for the development of its Sarconeos (BIO101). The company was founded in 2006 and is headquartered in Paris, France.

Details
Name: Biophytis SA
6XB
Exchange: DB
Founded: 2006
€21,123,902
39,118,338
Website: http://www.biophytis.com
Address: Biophytis SA
Sorbonne Université,
Bâtiment A 4 ème étage,
Paris,
Ile-de-France, 75252,
France
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
ENXTPA ALBPS Common Stock Euronext Paris FR EUR 13. Jul 2015
DB 6XB Common Stock Deutsche Boerse AG DE EUR 13. Jul 2015
LSE 0D1W Common Stock London Stock Exchange GB EUR 13. Jul 2015
Number of employees
Current staff
Staff numbers
23
Biophytis employees.
Industry
Biotechnology
Pharmaceuticals & Biotech
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2020/04/08 23:13
End of day share price update: 2020/04/08 00:00
Last estimates confirmation: 2019/05/20
Last earnings filing: 2020/03/17
Last earnings reported: 2019/12/31
Last annual earnings reported: 2019/12/31


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.